Incyte (INCY) Receives a Hold from Mizuho Securities
According to TipRanks, Goldstein is an analyst with an average return of -4.9% and a 31.31% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Merck & Company, Incyte, and Arcus Biosciences.
In addition to Mizuho Securities, Incyte also received a Hold from Morgan Stanley’s Vikram Purohit in a report issued on March 6. However, on March 7, JMP Securities reiterated a Buy rating on Incyte (NASDAQ: INCY).
INCY market cap is currently $16.41B and has a P/E ratio of 48.38.
Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year. Last month, Dhanak Dashyant, the EVP & Chief Scientific Officer of INCY bought 3,693.00 shares for a total of $241,596.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY:
- Incyte enters precision medicine strategic partnership with Caris Life Sciences
- Incyte to discontinue Phase 3 LIMBER-304 trial
- Incyte announces CHMP recommendation for approval of ruxolitinib cream
- Incyte announces 52-week results from povorcitinib trial
- Incyte price target raised to $100 from $95 at Cowen